PE20121732A1 - Derivados de ciclohexano espiro-condensado como inhibidores de hsl utiles en el tratamiento de la diabetes - Google Patents

Derivados de ciclohexano espiro-condensado como inhibidores de hsl utiles en el tratamiento de la diabetes

Info

Publication number
PE20121732A1
PE20121732A1 PE2012000489A PE2012000489A PE20121732A1 PE 20121732 A1 PE20121732 A1 PE 20121732A1 PE 2012000489 A PE2012000489 A PE 2012000489A PE 2012000489 A PE2012000489 A PE 2012000489A PE 20121732 A1 PE20121732 A1 PE 20121732A1
Authority
PE
Peru
Prior art keywords
phenyl
hsl
spiro
diabetes
treatment
Prior art date
Application number
PE2012000489A
Other languages
English (en)
Inventor
Jean Ackermann
Stephan Brugger
Aurelia Conte
Daniel Huziker
Werner Neidhart
Matthias Nettekoven
Tanja Schulz-Gasch
Stanley Wertheimer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20121732A1 publication Critical patent/PE20121732A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/54—Spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE CICLOHEXANO ESPIRO-CONDENSADO DE FORMULA (I) DONDE R1 ES ALQUILO, FENILO, FENILALQUILO, PIRIDINILO, PIRAZOLILO, ENTRE OTROS; R2 ES H, ALQUILO, CICLOALQUILO, OXETANILALCOXILALQUILO, HIDROXIALQUILO, ENTRE OTROS; R3 ES R4-A- O ESTA AUSENTE SI Ca Y Cb SE UNEN POR UN DOBLE ENLACE, EN DONDE R4 ES H, ALQUILO, CICLOALQUILO, FENILO, ENTRE OTROS; A ES O, S, S(O), S(O)2, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (5a,8b)-8-HIDROXI-2-(4-TRIFLUOROMETOXI-FENIL)-2-AZA-ESPIRO[4.5]DECAN-1-ONA; (5a,8b)-2-(4-ETIL-FENIL)-1-OXO-2-AZA-ESPIRO[4.5]DEC-8-IL] ESTER DEL ACIDO (3-FLUORO-BENCIL)-CARBAMICO; (5a,8b)-8-HIDROXI-8-ISOPROPIL-2-[4-(2,2,2-TRIFLUORO-ETOXI)-FENIL]-2-AZA-ESPIRO[4.5]DECAN-1-ONA; ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION Y UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA LIPASA SENSIBLE A HORMONAS (HSL) SIENDO UTILES EN EL TRATAMIENTO DE DIABETES, SINDROME METABOLICO, OBESIDAD
PE2012000489A 2009-10-15 2010-10-12 Derivados de ciclohexano espiro-condensado como inhibidores de hsl utiles en el tratamiento de la diabetes PE20121732A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09173178 2009-10-15

Publications (1)

Publication Number Publication Date
PE20121732A1 true PE20121732A1 (es) 2012-12-28

Family

ID=43093680

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000489A PE20121732A1 (es) 2009-10-15 2010-10-12 Derivados de ciclohexano espiro-condensado como inhibidores de hsl utiles en el tratamiento de la diabetes

Country Status (20)

Country Link
US (1) US8440710B2 (es)
EP (1) EP2488493B1 (es)
JP (1) JP5749272B2 (es)
KR (1) KR101576328B1 (es)
CN (1) CN102858743B (es)
AR (1) AR078619A1 (es)
AU (1) AU2010305859A1 (es)
BR (1) BR112012008962A2 (es)
CA (1) CA2776457A1 (es)
CL (1) CL2012000937A1 (es)
ES (1) ES2538005T3 (es)
HK (1) HK1179957A1 (es)
IL (1) IL218958A0 (es)
IN (1) IN2012DN03337A (es)
MX (1) MX2012004311A (es)
PE (1) PE20121732A1 (es)
RU (1) RU2607080C2 (es)
TW (1) TW201118068A (es)
WO (1) WO2011045292A1 (es)
ZA (1) ZA201202613B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010109329A1 (en) 2009-03-23 2010-09-30 Glenmark Pharmaceuticals, S.A. Furopyrimidinedione derivatives as trpa1 modulators
US8097634B2 (en) * 2010-04-15 2012-01-17 Hoffmann-La Roche Inc. Azacyclic derivatives
US8722721B2 (en) * 2011-03-16 2014-05-13 Hoffmann-La Roche Inc. SEC-hydroxycyclohexyl derivatives
US8703807B2 (en) * 2011-03-17 2014-04-22 Hoffmann-La Roche Inc. Azaspirodecanone compounds
US8809384B2 (en) * 2011-03-25 2014-08-19 Hoffmann-La Roche Inc. Azaspirodecanone compounds
CN103319395B (zh) * 2013-04-08 2014-09-24 武汉罗化科技有限公司 一种4-氟靛红的工业化制备方法及其产品
WO2015103756A1 (en) 2014-01-09 2015-07-16 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
UY36060A (es) 2014-04-02 2015-10-30 Bayer Pharma AG Compuestos de azol sustituidos con amida
KR20200083529A (ko) 2017-11-01 2020-07-08 브리스톨-마이어스 스큅 컴퍼니 파르네소이드 x 수용체 조정제로서의 알켄 스피로시클릭 화합물
WO2019089664A1 (en) 2017-11-01 2019-05-09 Bristol-Myers Squibb Company Multicyclic compounds as farnesoid x receptor modulators
PE20201170A1 (es) 2017-11-01 2020-10-28 Bristol Myers Squibb Co Compuestos biciclicos en puente como moduladores del receptor farnesoide x
WO2019089670A1 (en) 2017-11-01 2019-05-09 Bristol-Myers Squibb Company Alkene compounds as farnesoid x receptor modulators
AU2018357878A1 (en) 2017-11-01 2020-06-18 Bristol-Myers Squibb Company Spirocyclic compounds as farnesoid X receptor modulators
CN109369354B (zh) * 2018-12-15 2021-07-09 浦拉司科技（上海）有限责任公司 一种4,4,4-三氟丁醇的合成方法
AR118050A1 (es) 2019-02-15 2021-09-15 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10247680B4 (de) * 2002-10-12 2005-09-01 Aventis Pharma Deutschland Gmbh Neue bicyclische Inhibitoren der Hormon Sensitiven Lipase
US7320992B2 (en) 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
WO2005061497A1 (en) 2003-12-16 2005-07-07 Pfizer Products Inc. Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors
FR2870538B1 (fr) * 2004-05-19 2006-07-14 Servier Lab Nouveaux derives de pyrrolidines et de thiazolidines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2007103719A2 (en) 2006-03-03 2007-09-13 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
EP2021337B1 (en) * 2006-04-25 2010-01-13 Eli Lilly And Company Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
PT2035379E (pt) 2006-04-25 2010-07-13 Lilly Co Eli Inibidores da 11-beta-hidroxiesterëide desidrogenase 1
GB0705656D0 (en) 2007-03-23 2007-05-02 Addex Pharmaceuticals Sa Novel compounds E1

Also Published As

Publication number Publication date
CN102858743A (zh) 2013-01-02
AR078619A1 (es) 2011-11-23
IL218958A0 (en) 2012-06-28
HK1179957A1 (en) 2013-10-11
KR20120074304A (ko) 2012-07-05
BR112012008962A2 (pt) 2019-09-24
TW201118068A (en) 2011-06-01
JP2013507421A (ja) 2013-03-04
CA2776457A1 (en) 2011-04-21
RU2012119706A (ru) 2013-11-20
ES2538005T3 (es) 2015-06-16
US20110092512A1 (en) 2011-04-21
US8440710B2 (en) 2013-05-14
WO2011045292A1 (en) 2011-04-21
KR101576328B1 (ko) 2015-12-10
EP2488493A1 (en) 2012-08-22
RU2607080C2 (ru) 2017-01-10
MX2012004311A (es) 2012-04-30
ZA201202613B (en) 2013-01-30
AU2010305859A1 (en) 2012-06-07
IN2012DN03337A (es) 2015-10-23
CL2012000937A1 (es) 2012-09-14
JP5749272B2 (ja) 2015-07-15
EP2488493B1 (en) 2015-04-15
CN102858743B (zh) 2015-06-10

Similar Documents

Publication Publication Date Title
PE20121732A1 (es) Derivados de ciclohexano espiro-condensado como inhibidores de hsl utiles en el tratamiento de la diabetes
UY29575A1 (es) Formas polimórficas del éster etílico del ácido 3-((2-((4-(hexiloxicarbonilamino--imino-metil)-fenilamino)-metil)-1-metil-h-bencimidazol-5-carbonil)-piridin-2-il- -amino)-propiónico
PE20110136A1 (es) Compuestos organicos
PE20091002A1 (es) Analogos dipeptidos como inhibidores del factor de coagulacion
UY28493A1 (es) Metanosulfonato del éster etílico del ácido 3-((2-((4-(hexiloxicarbonilamino-imino-metil)-fenilamino)-metil)-1-metil-1h-bencimidazol-5-carbonil)-piridin-2-il-amino)-propiónico y su utilización como medicamento.
CL2008000422A1 (es) El compuesto acido 4-[4-(2-adamantilcarbamoil)-5-terbutilpirazol-1-il]-benzoico; composicion farmaceutica; su uso como inhibidor de 11bhsd1, util en el tratamiento de la diabetes tipo 2 y la obesidad.
NZ601121A (en) 5-alkynyl-pyrimidines
NZ716420A (en) Fused heterocyclic compounds as sodium channel modulators
PE20120690A1 (es) Derivados de 5-fluoropirimidinona
EA201101671A1 (ru) Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина
NO20084418L (no) Azolopyridin-3-on derivater som inhibitorer av endoteliallipase
PE20141408A1 (es) Aminoquinazolinas como inhibidores de quinasa
PE20131116A1 (es) Compuestos heterociclicos potenciadores de ampa
NO20091560L (no) Biaryleterureaforbindelser
PE20091828A1 (es) Derivados de acido ciclopentanocarboxilico condensados sustituidos con acilamino como inhibidores de edg-2
PE20120585A1 (es) Forma cristalina del fosfato de dihidrogeno r)-3-(4-(2-(2-metiltetrazol-5-il) piridin-5-il)-3-fluorofensil)-5-hidroximetil oxazolidin-2-ona
PE20081704A1 (es) Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa
MX2010008583A (es) Novedosos formas cristalinas de acido 4-[4-(2-adamantilcarbamoil)- 5-ter-butil-pirazol-1-il]benzoico.
WO2012161518A3 (ko) ＲＯＲα의 활성자로서의 신규한 ｔｈｉｏｕｒｅａ 유도체 및 이를 함유하는 약학적 조성물
PE20151666A1 (es) Derivados sustituidos del acido bisfenil butanoico fosfonico como inhibidores de la nep
EA201100354A1 (ru) Полиморф в n-(2-аминофенил)-4-[n-(пиридин-3-ил)-метоксикарбониламинометил]бензамида (ms-275)
WO2013012485A3 (en) Novel crystalline forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
PE20142399A1 (es) Compuestos de pirazol como inhibidores de sglt1
WO2009127949A8 (en) 4- [3- (aryloxy) benzylidene] -3-methyl piperidine aryl carboxamide compounds useful as faah inhibitors
PE20140018A1 (es) Una composicion que comprende 2-metilpropanotioato de s-[2-([[1-(2-etilbutil)ciclohexil]-carbonil]amino)fenilo] y croscarmelosa sodica

Legal Events

Date Code Title Description
FA Abandonment or withdrawal